Management of psoriasis patients with hepatitis B or hepatitis C virus infection

Table 2 Diagnosis and distribution of patients treated with tumor necrosis factor-α inhibitors according to the hepatitis B virus serological profile

Ref.	Diagnosis, n	Inactive carriers (HBsAg+), n	Occult carriers or resolved HBV (anti-HBc+, anti-HBs- or anti-HBs ± anti-HBc), n	Prophylaxis2, n	Reactivation, n
Charpin et al[42]	PsA, 5	0	5	0	0
Prestinari et al[43]	PsO, 1	0	1	0	0
Nosotti et al[44]	PsO, 4; PsA, 3	1	6	1 (Lamivudine)	0
Caporali et al[45]	PsA, 4	0	4	0	0
Kim et al[46]	PsA, 2	0	2	0	0
Fotadiou et al[47]	PsO, 7	7	0	7 (Lamivudine)	0
Prignano et al[48]	PsO, 12	0	12	0	0
Cassano et al[49]	PsO, 28; PsA, 34	0	62	0	0
Cho et al[50]	PsA, 2	2	0	0	1
Navarro et al[51]	PsO, 13	0	13	0	0
Laurenti et al[52]	PsA, 8	1	7	1 (Lamivudine)	0
Navarro et al[53]	PsO, 4	4	0	3 (Lamivudine); 1 (adefovir2 entecavir)	0
1Sanz-Bueno et al[54]	PsO, 20	0	20	0	0

¹This group also includes 6 patients who received UTK;

²Only inactive carriers. PsO: Psoriasis; PsA: Psoriatic arthritis.